Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.49 USD | -2.05% | -25.34% | +26.26% |
04-17 | North American Morning Briefing : Stock Futures -2- | DJ |
04-16 | Oppenheimer Upgrades Avalo Therapeutics to Outperform From Perform, Price Target is $35 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+26.26% | 12.13M | |
+23.37% | 46.71B | |
+48.83% | 41.8B | |
-0.94% | 41.52B | |
-5.86% | 29.55B | |
+11.29% | 25.78B | |
-20.92% | 19.26B | |
+3.20% | 12.14B | |
-2.67% | 12.08B | |
+30.23% | 11.98B |
- Stock Market
- Equities
- AVTX Stock
- News Avalo Therapeutics, Inc.
- RBC Cuts Price Target on Avalo Therapeutics to $4 From $5, Maintains Outperform Rating, Speculative Risk Qualifier